GB201610044D0 - Antibodies - Google Patents

Antibodies

Info

Publication number
GB201610044D0
GB201610044D0 GBGB1610044.8A GB201610044A GB201610044D0 GB 201610044 D0 GB201610044 D0 GB 201610044D0 GB 201610044 A GB201610044 A GB 201610044A GB 201610044 D0 GB201610044 D0 GB 201610044D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1610044.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Priority to GBGB1610044.8A priority Critical patent/GB201610044D0/en
Publication of GB201610044D0 publication Critical patent/GB201610044D0/en
Priority to EA201892774A priority patent/EA201892774A1/ru
Priority to US16/307,444 priority patent/US10766956B2/en
Priority to MX2018014376A priority patent/MX2018014376A/es
Priority to BR112018074869-2A priority patent/BR112018074869A2/pt
Priority to PCT/EP2017/063796 priority patent/WO2017211873A1/en
Priority to EP17729444.4A priority patent/EP3468992A1/en
Priority to AU2017276685A priority patent/AU2017276685A1/en
Priority to RU2018146158A priority patent/RU2746926C2/ru
Priority to CN201780035444.0A priority patent/CN109311970A/zh
Priority to JP2018564217A priority patent/JP2019520818A/ja
Priority to CA3024011A priority patent/CA3024011A1/en
Priority to KR1020197000199A priority patent/KR20190015497A/ko
Priority to ARP170101556A priority patent/AR108779A1/es
Priority to SG11201810311WA priority patent/SG11201810311WA/en
Priority to TW106119141A priority patent/TW201802115A/zh
Priority to UY0001037279A priority patent/UY37279A/es
Priority to CONC2018/0012513A priority patent/CO2018012513A2/es
Priority to IL263425A priority patent/IL263425A/en
Priority to CL2018003510A priority patent/CL2018003510A1/es
Priority to US16/925,281 priority patent/US11518803B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1610044.8A 2016-06-08 2016-06-08 Antibodies Ceased GB201610044D0 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GBGB1610044.8A GB201610044D0 (en) 2016-06-08 2016-06-08 Antibodies
SG11201810311WA SG11201810311WA (en) 2016-06-08 2017-06-07 Antagonist antibodies that t bind to human tgfb1, tgfb2 and to tgfb3 and their use for the treatment of lung fibrosis
JP2018564217A JP2019520818A (ja) 2016-06-08 2017-06-07 ヒトｔｇｆｂ１、ｔｇｆｂ２及びｔｇｆｂ３に結合するアンタゴニスト抗体、及び肺線維症を治療するためのそれらの使用
KR1020197000199A KR20190015497A (ko) 2016-06-08 2017-06-07 인간 ｔｇｆｂ1, ｔｇｆｂ2에, 및 ｔｇｆｂ3에 결합하는 길항제 항체, 및 폐 섬유증 치료를 위한 그의 용도
MX2018014376A MX2018014376A (es) 2016-06-08 2017-06-07 Anticuerpos antagonistas que unen t a tgfb1, tgfb2 y a tgfb3 humanos y su uso para tratamiento de fibrosis pulmonar.
BR112018074869-2A BR112018074869A2 (pt) 2016-06-08 2017-06-07 anticorpos antagonistas que ligam t ao tgfb1, tgfb2 e ao tgfb3 humanos e seu uso para o tratamento de fibrose pulmonar
PCT/EP2017/063796 WO2017211873A1 (en) 2016-06-08 2017-06-07 Antagonist antibodies that t bind to human tgfb1, tgfb2 and to tgfb3 and their use for the treatment of lung fibrosis
EP17729444.4A EP3468992A1 (en) 2016-06-08 2017-06-07 Antagonist antibodies that t bind to human tgfb1, tgfb2 and to tgfb3 and their use for the treatment of lung fibrosis
AU2017276685A AU2017276685A1 (en) 2016-06-08 2017-06-07 Antagonist antibodies that t bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosis
RU2018146158A RU2746926C2 (ru) 2016-06-08 2017-06-07 Антагонистические антитела, которые связываются с человеческими TGFβ1, TGFβ2 и TGFβ3, и их применение при лечении фиброза легких
CN201780035444.0A CN109311970A (zh) 2016-06-08 2017-06-07 结合人TGF-β1、人TGF-β2和人TGF-β3的拮抗性抗体及其用于治疗肺纤维化的用途
EA201892774A EA201892774A1 (ru) 2016-06-08 2017-06-07 Антитела
CA3024011A CA3024011A1 (en) 2016-06-08 2017-06-07 Antagonist antibodies that t bind to human tgfb1, tgfb2 and to tgfb3 and their use for the treatment of lung fibrosis
US16/307,444 US10766956B2 (en) 2016-06-08 2017-06-07 Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosis
ARP170101556A AR108779A1 (es) 2016-06-08 2017-06-07 Anticuerpos
UY0001037279A UY37279A (es) 2016-06-08 2017-06-08 Anticuerpos tgf-beta y fragmentos de unión de los mismos
TW106119141A TW201802115A (zh) 2016-06-08 2017-06-08 抗體
CONC2018/0012513A CO2018012513A2 (es) 2016-06-08 2018-11-22 Anticuerpos
IL263425A IL263425A (en) 2016-06-08 2018-12-02 Antagonistic t-linked antibodies to human tgfb2, tgfb1 and tgfb3 and their use for the treatment of pulmonary fibrosis
CL2018003510A CL2018003510A1 (es) 2016-06-08 2018-12-06 Anticuerpos antagonistas que se unen en forma de t a tgfb1, tgfb2 y tgfb3 humano, y su uso en el tratamiento de fibrosis pulmonar.
US16/925,281 US11518803B2 (en) 2016-06-08 2020-07-09 Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1610044.8A GB201610044D0 (en) 2016-06-08 2016-06-08 Antibodies

Publications (1)

Publication Number Publication Date
GB201610044D0 true GB201610044D0 (en) 2016-07-20

Family

ID=56508288

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1610044.8A Ceased GB201610044D0 (en) 2016-06-08 2016-06-08 Antibodies

Country Status (20)

Country Link
US (2) US10766956B2 (https=)
EP (1) EP3468992A1 (https=)
JP (1) JP2019520818A (https=)
KR (1) KR20190015497A (https=)
CN (1) CN109311970A (https=)
AR (1) AR108779A1 (https=)
AU (1) AU2017276685A1 (https=)
BR (1) BR112018074869A2 (https=)
CA (1) CA3024011A1 (https=)
CL (1) CL2018003510A1 (https=)
CO (1) CO2018012513A2 (https=)
EA (1) EA201892774A1 (https=)
GB (1) GB201610044D0 (https=)
IL (1) IL263425A (https=)
MX (1) MX2018014376A (https=)
RU (1) RU2746926C2 (https=)
SG (1) SG11201810311WA (https=)
TW (1) TW201802115A (https=)
UY (1) UY37279A (https=)
WO (1) WO2017211873A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
SG11201907299XA (en) 2017-02-08 2019-09-27 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
IL268755B2 (en) 2017-02-20 2025-12-01 Dragonfly Therapeutics Inc Proteins that bind her2, nkg2d, and cd16
EA202091887A1 (ru) 2018-02-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
MX2021000347A (es) 2018-07-11 2021-04-19 Scholar Rock Inc Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos.
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
JP2022548776A (ja) * 2019-09-19 2022-11-21 ノースウェスタン ユニバーシティ ヒト人工多能性幹細胞のための費用効果の高い培地およびプロトコル
KR102270700B1 (ko) * 2019-11-01 2021-06-30 한국과학기술연구원 폐 섬유증의 예방 또는 치료를 위한 올리고뉴클레오티드 중합체와 생체 적합성 양이온성 펩타이드로 이루어지는 폐 특이적 약물 전달체 및 이의 이용
TWI867190B (zh) * 2020-03-19 2024-12-21 美商建南德克公司 同功型選擇性抗-TGF-β抗體及其使用方法
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
CA3199324A1 (en) * 2020-11-17 2022-05-27 Adam Marc Silverstein Inhaled imatinib for pulmonary hypertension field
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
CN112961240B (zh) * 2021-04-06 2022-07-05 明济生物制药（北京）有限公司 一种靶向TGF-β1的单克隆抗体及其与间充质干细胞外泌体的联合应用
CN112940119B (zh) * 2021-04-26 2022-05-20 北京芳渟阳生生物科技有限公司 一种单克隆抗体及其与间充质干细胞外泌体的联合应用
US20250127716A1 (en) * 2022-02-04 2025-04-24 Justus-Liebig-Universitaet Giessen Inhaled imatinib for treatment of pulmonary hypertension

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020141995A1 (en) * 1997-06-10 2002-10-03 Irvin Charles G. Method for treatment of inflammatory disease
EP1636270B1 (en) * 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
CN1961003B (zh) * 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
WO2006086469A2 (en) * 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
JP2009521496A (ja) 2005-12-23 2009-06-04 イーライ リリー アンド カンパニー ＴＧＦ−β結合組成物
DK2083863T3 (da) * 2006-10-03 2015-06-22 Genzyme Corp Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi
SG195253A1 (en) * 2011-06-03 2013-12-30 Xoma Technology Ltd Antibodies specific for tgf-beta
PT2971048T (pt) 2013-03-11 2019-02-06 Genzyme Corp Anticorpos anti-tgf-beta manipulados e fragmentos de ligação a antigénios
CN106794233B (zh) 2014-08-01 2021-11-12 布里格姆及妇女医院股份有限公司 与肺动脉高压的治疗有关的组合物和方法
JP2019511911A (ja) 2016-02-17 2019-05-09 ノバルティス アーゲー Ｔｇｆベータ２抗体
EP3571227A1 (en) 2017-01-20 2019-11-27 Sanofi Anti-tgf-beta antibodies and their use

Also Published As

Publication number Publication date
BR112018074869A2 (pt) 2019-03-26
JP2019520818A (ja) 2019-07-25
CN109311970A (zh) 2019-02-05
EA201892774A1 (ru) 2019-05-31
AR108779A1 (es) 2018-09-26
TW201802115A (zh) 2018-01-16
CO2018012513A2 (es) 2019-02-08
SG11201810311WA (en) 2018-12-28
IL263425A (en) 2018-12-31
US10766956B2 (en) 2020-09-08
WO2017211873A1 (en) 2017-12-14
EP3468992A1 (en) 2019-04-17
KR20190015497A (ko) 2019-02-13
CL2018003510A1 (es) 2019-02-01
MX2018014376A (es) 2019-03-14
RU2018146158A (ru) 2020-07-09
US20200407436A1 (en) 2020-12-31
RU2746926C2 (ru) 2021-04-22
CA3024011A1 (en) 2017-12-14
AU2017276685A1 (en) 2018-11-29
US11518803B2 (en) 2022-12-06
RU2018146158A3 (https=) 2020-07-09
UY37279A (es) 2018-01-31
US20190330321A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
ZA201900373B (en) Anti-tim-3 antibodies
IL259048A (en) Antibodies against ror-1
SG10201601719RA (en) Anti-LAG-3 Antibodies
GB201601073D0 (en) Antibodies
SG10201913864RA (en) Anti-LAG-3 Antibodies
GB201621439D0 (en) IL-11Ra Antibodies
IL253633A0 (en) Anti-transthyretin antibodies
GB201521393D0 (en) Antibodies
GB201610044D0 (en) Antibodies
GB201521391D0 (en) Antibodies
PL3250593T3 (pl) Przeciwciała przeciwko transtyretynie
SG10202010735PA (en) Tau-binding antibodies
GB201521382D0 (en) Antibodies
IL255323A0 (en) Anti-fcrn antibodies
GB201616699D0 (en) Antibodies
ZA201808317B (en) Anti-tnfrsf25 antibodies
GB201603291D0 (en) Antibodies
PT3484921T (pt) Anticorpos anti-il-22r
IL260083A (en) Antibody against myl9
GB201509907D0 (en) Antibodies
GB201503438D0 (en) Antibodies
GB201522394D0 (en) Antibodies
IL284022A (en) Anti-transthyretin antibodies
GB201622197D0 (en) Antibodies
GB201620414D0 (en) Antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)